Literature DB >> 10352646

Influence of age on characteristics of polymyositis and dermatomyositis in adults.

I Marie1, P Y Hatron, H Levesque, E Hachulla, M F Hellot, U Michon-Pasturel, H Courtois, B Devulder.   

Abstract

In a retrospective study of 79 consecutive patients, we evaluated characteristics of polymyositis (PM) and dermatomyositis (DM) and compared clinical presentation, biochemical findings, histologic changes, evolution, complications, and mortality rate of elderly patients (aged > or = 65 yr) and younger patients (aged < or = 64 yr) at the onset of PM/DM. We found a high prevalence of PM/DM in elderly patients: 23 patients (29%) were aged 65 years or over. We also found that esophageal involvement (34.8% versus 16.1%, respectively) and bacterial pneumonia related to both ventilatory insufficiency and esophageal impairment (21.7% versus 5.4%, respectively) were more common in elderly patients compared with younger patients, resulting in increased morbidity and mortality rates. Moreover, malignancy frequency was higher in elderly patients compared with younger patients (47.8% versus 9.1%, respectively, p = 0.0001), particularly patients with DM (10/11). Fifty percent of malignancies were colon malignancies in elderly patients. Erythrocyte sedimentation rate, C-reactive protein, fibrinogen, and ferritin levels were also higher in the elderly patient group compared with the younger group, and the presence of serum hypoprotidemia, hypoalbuminemia, and anemia was more frequent. Finally, PM/DM complete remission was less frequent (13.6% versus 41.1%) and the mortality rate (47.8% versus 7.3%) was higher in elderly patients than in younger patients. The main causes of death in elderly patients were bacterial pneumonia, due to ventilatory insufficiency and esophageal impairment, and malignancies. Our findings therefore indicate that PM/DM-related esophageal and lung involvement should be systematically searched for in elderly patients. Esophageal manometry and pulmonary function tests should become an integral part of initial evaluation in elderly patients for early detection of impairment. Moreover, as we observed a marked overrepresentation of colon cancer in elderly patients with DM, we suggest that the search for malignancies in elderly patients with DM should include lower gastrointestinal tract investigations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352646     DOI: 10.1097/00005792-199905000-00001

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  31 in total

Review 1.  Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Authors:  Lauren M Pachman; Adele L Boskey
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

2.  Prognosis and mortality of polymyositis and dermatomyositis patients.

Authors:  A Airio; H Kautiainen; M Hakala
Journal:  Clin Rheumatol       Date:  2006-02-14       Impact factor: 2.980

3.  Long-term follow-up of 62 patients with myositis.

Authors:  Janneke van de Vlekkert; Jessica E Hoogendijk; Marianne de Visser
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

4.  When myopathy strikes in a cancer patient.

Authors:  Srivalli Gopaluni; Lilian M Thomas; Chirag Shah
Journal:  Gastrointest Cancer Res       Date:  2009-09

5.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

6.  Inflammatory myopathies: One-center experience.

Authors:  Metin Işık; Şule Bilgen; İsmail Doğan; Levent Kılıç
Journal:  Eur J Rheumatol       Date:  2014-09-01

Review 7.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

8.  Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Authors:  Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

Review 9.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

10.  Clinical characteristics and outcomes of juvenile and adult dermatomyositis.

Authors:  Sang-Jun Na; Seung Min Kim; Il Nam Sunwoo; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.